Verastem, Inc. (0LOV.L)

USD 4.46

(-3.44%)

Long Term Debt Summary of Verastem, Inc.

  • Verastem, Inc.'s latest annual long term debt in 2023 was 40.08 Million USD , up 54.2% from previous year.
  • Verastem, Inc.'s latest quarterly long term debt in 2024 Q2 was 35.39 Million USD , down -11.8% from previous quarter.
  • Verastem, Inc. reported annual long term debt of 25.99 Million USD in 2022, up 1048.23% from previous year.
  • Verastem, Inc. reported annual long term debt of 2.26 Million USD in 2021, down -89.7% from previous year.
  • Verastem, Inc. reported quarterly long term debt of 50.32 Million USD for 2024 Q1, up 0.09% from previous quarter.
  • Verastem, Inc. reported quarterly long term debt of 40.69 Million USD for 2023 Q3, down -0.17% from previous quarter.

Annual Long Term Debt Chart of Verastem, Inc. (2023 - 2011)

Historical Annual Long Term Debt of Verastem, Inc. (2023 - 2011)

Year Long Term Debt Long Term Debt Growth
2023 40.08 Million USD 54.2%
2022 25.99 Million USD 1048.23%
2021 2.26 Million USD -89.7%
2020 21.98 Million USD -79.48%
2019 107.11 Million USD -6.65%
2018 114.73 Million USD 673.79%
2017 14.82 Million USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%

Peer Long Term Debt Comparison of Verastem, Inc.

Name Long Term Debt Long Term Debt Difference
Editas Medicine, Inc. 24.37 Million USD -64.476%
Dynavax Technologies Corporation 252.41 Million USD 84.119%
Supernus Pharmaceuticals, Inc. 33.19 Million USD -20.756%
Perrigo Company plc 3.63 Billion USD 98.897%
Illumina, Inc. 1.48 Billion USD 97.308%
Thermo Fisher Scientific Inc. 31.3 Billion USD 99.872%
Iovance Biotherapeutics, Inc. 1 Million USD -3908.6%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 99.502%
IQVIA Holdings Inc. 12.95 Billion USD 99.691%
Heron Therapeutics, Inc. 173.75 Million USD 76.929%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 98.517%
Unity Biotechnology, Inc. 23.53 Million USD -70.296%
Waters Corporation 2.3 Billion USD 98.261%
Biogen Inc. 7.18 Billion USD 99.442%
Sangamo Therapeutics, Inc. 33.51 Million USD -19.606%
Evolus, Inc. 120.35 Million USD 66.695%
Adicet Bio, Inc. 17.7 Million USD -126.436%
Cara Therapeutics, Inc. 37.07 Million USD -8.11%
bluebird bio, Inc. 224.41 Million USD 82.138%
Esperion Therapeutics, Inc. 501.54 Million USD 92.008%
FibroGen, Inc. 89.69 Million USD 55.31%
Agilent Technologies, Inc. 2.73 Billion USD 98.534%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD -1137.745%
Homology Medicines, Inc. 43.17 Million USD 7.157%
Geron Corporation 35.05 Million USD -14.365%
Alnylam Pharmaceuticals, Inc. 2.34 Billion USD 98.289%
Amicus Therapeutics, Inc. 387.85 Million USD 89.665%
Myriad Genetics, Inc. 130.9 Million USD 69.377%
Viking Therapeutics, Inc. 936 Thousand USD -4182.692%
Intellia Therapeutics, Inc. 96.74 Million USD 58.566%
Zoetis Inc. 6.56 Billion USD 99.389%
Abeona Therapeutics Inc. 4.4 Million USD -810.632%
Mettler-Toledo International Inc. 1.97 Billion USD 97.971%
BioMarin Pharmaceutical Inc. 593.09 Million USD 93.241%
Vertex Pharmaceuticals Incorporated 724.7 Million USD 94.469%
Kala Pharmaceuticals, Inc. 34.19 Million USD -17.245%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD 97.137%
Atara Biotherapeutics, Inc. 45.69 Million USD 12.271%
Nektar Therapeutics 112.62 Million USD 64.408%
Axsome Therapeutics, Inc. 178.07 Million USD 77.489%
Aclaris Therapeutics, Inc. 3.07 Million USD -1204.034%
Sarepta Therapeutics, Inc. 1.13 Billion USD 96.46%
OPKO Health, Inc. 222.03 Million USD 81.946%
Exelixis, Inc. 189.94 Million USD 78.896%
Neurocrine Biosciences, Inc. 258.3 Million USD 84.481%
Corcept Therapeutics Incorporated - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
uniQure N.V. 130.06 Million USD 69.18%
Imunon, Inc. 1.13 Million USD -3418.498%
Blueprint Medicines Corporation 610.96 Million USD 93.439%
Insmed Incorporated 1.19 Billion USD 96.641%
Halozyme Therapeutics, Inc. 1.49 Billion USD 97.326%
Agios Pharmaceuticals, Inc. 56.98 Million USD 29.659%
TG Therapeutics, Inc. 100.11 Million USD 59.961%
Incyte Corporation 29.16 Million USD -37.46%
Emergent BioSolutions Inc. 446.5 Million USD 91.022%